Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
5.3 USD | -5.02% | -0.93% | +22.40% |
Financials (USD)
Sales 2024 * | 231M | Sales 2025 * | 233M | Capitalization | 255M |
---|---|---|---|---|---|
Net income 2024 * | 13M | Net income 2025 * | 14M | EV / Sales 2024 * | 1.11 x |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 1.1 x |
P/E ratio 2024 * |
20.5
x | P/E ratio 2025 * |
31.4
x | Employees | 185 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 84.88% |
Latest transcript on Puma Biotechnology, Inc.
1 day | -5.02% | ||
1 week | -0.93% | ||
Current month | -14.79% | ||
1 month | -19.70% | ||
3 months | +21.84% | ||
6 months | +100.00% | ||
Current year | +22.40% |
Managers | Title | Age | Since |
---|---|---|---|
Alan Auerbach
CEO | Chief Executive Officer | 54 | 10-09-14 |
Maximo Nougues
DFI | Director of Finance/CFO | 55 | 18-11-04 |
Alvin Wong
CTO | Chief Tech/Sci/R&D Officer | 71 | 13-02-28 |
Members of the board | Title | Age | Since |
---|---|---|---|
Michael Miller
BRD | Director/Board Member | 67 | 18-02-22 |
Jay Moyes
BRD | Director/Board Member | 70 | 12-04-26 |
Alan Auerbach
CEO | Chief Executive Officer | 54 | 10-09-14 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.01% | 0 M€ | 0.00% | - | |
0.01% | 2 M€ | -.--% |
Date | Price | Change | Volume |
---|---|---|---|
24-03-28 | 5.3 | -5.02% | 275,380 |
24-03-27 | 5.58 | -0.36% | 357,785 |
24-03-26 | 5.6 | +0.18% | 528,485 |
24-03-25 | 5.59 | +4.88% | 738,420 |
24-03-22 | 5.33 | -0.37% | 924,299 |
Delayed Quote Nasdaq, March 28, 2024 at 04:30 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+22.40% | 255M | |
+9.30% | 46.03B | |
+52.73% | 44.55B | |
+7.15% | 40.8B | |
-8.78% | 28.25B | |
+18.68% | 27.71B | |
-21.92% | 18.82B | |
+14.62% | 13.91B | |
+31.85% | 12.43B | |
+4.47% | 10.81B |